Skip to content
Menu

Century Therapeutics, Inc. IPSC

Full chart Compare
Set alert

Price alert · IPSC

All alert types
1.20 USD -0.12 (-9.09%)

As ofNov 20, 2026, 11:57 AM EST

1.19 Day range 1.22
0.464 52-week range 3.04
YTD
+20.60%
1 year
+144.40%

5D -0.34 (-19.77%)

1.401.60ThuFriMonTueWed1.38
Market cap
216.28M
Revenue (ttm)
2.68M
EPS (ttm)
-0.64
Shares out
85.03M
Forward P/E
-0.76
YTD return
+20.60%
1-year return
+144.40%
50-day average
1.38
200-day average
2.38
Volume
343.62K
Avg volume
750.54K
Open
1.22
Previous close
1.32
Day's range
1.19 – 1.22
52-week range
0.464 – 3.04
Beta
1.42
Analysts
Buy
Price target
9.67 (+705.6%)

Key statistics

Enterprise value
-49.98M
Price / sales
32.31
Price / book
0.44
Revenue growth
434.50%
Free cash flow
-62.05M
Total cash
198.11M
Total debt
54.60M
Return on equity
-62.61%
Short % of float
4.13%

Fundamental scorecard

3 of 25 checks passed on IPSC’s reported financials

ValueGrowthProfitabilityHealthDividend

3of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
IPSC Revenue — quarterly 0
IPSC Net income — quarterly -23.45M
IPSC EPS — quarterly -0.11

Earnings

IPSC recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 5, 2024Sep 1, 2024-0.46-0.37+0.09+19.57%
Aug 8, 2024Jun 1, 2024-0.50———
Aug 8, 2024Jun 1, 2024-0.50-0.38+0.12+24.00%
May 9, 2024Mar 1, 2024-0.50———
May 9, 2024Mar 1, 2024-0.50-0.45+0.05+10.00%
Mar 14, 2024Dec 1, 2023-0.56-0.49+0.07+12.50%

Upgrades / downgrades

IPSC analyst upgrades and downgrades
DateFirmActionFromTo
Nov 7, 2024Chardan CapitalmainBuyBuy
Nov 6, 2024HC Wainwright & Co.mainBuyBuy
Aug 15, 2024HC Wainwright & Co.mainBuyBuy
Jun 17, 2024Piper SandlermainOverweightOverweight
Jun 4, 2024HC Wainwright & Co.reitBuyBuy
May 10, 2024HC Wainwright & Co.mainBuyBuy

About Century Therapeutics, Inc.

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

No recent headlines

Headlines appear here as they are published.

Your note

Sign in to keep a note on IPSC — it syncs with the Stock Master app.

Insider holders

IPSC insider holders
InsiderRelationLatest transactionDateShares held
BORGES LUISOfficerConversion of Exercise of derivative securityApr 2, 2023256,535
CARR DOUGLASOfficerSaleNov 3, 2024317,147
CONN MORGAN PH.D.Chief Financial OfficerStock Award(Grant)Oct 13, 202460,148
COWAN CHADOfficerStock Award(Grant)Sep 30, 2024221,503
DIEM MICHAEL CRAIGChief Financial OfficerStock Award(Grant)May 14, 2023274,296
FARID ADRIENNEChief Operating OfficerSaleNov 3, 2024135,130

Institution ownership

IPSC institution ownership
Holder% heldSharesValueReported
Bain Capital Life Sciences Investors, LLC6.36%5,410,3615.52MSep 29, 2024
VR Adviser, LLC6.34%5,389,2595.50MSep 29, 2024
Boxer Capital, LLC4.59%3,900,0003.98MSep 29, 2024
Casdin Capital, LLC3.78%3,212,3163.28MSep 29, 2024
Blackrock Inc.3.52%2,989,9203.05MSep 29, 2024
FMR, LLC2.97%2,521,5112.57MSep 29, 2024

Fund ownership

IPSC fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund1.55%1,314,6211.34MSep 29, 2024
iShares Russell 2000 ETF1.21%1,026,9781.05MOct 30, 2024
Vanguard Extended Market Index Fund0.92%785,571801.28KSep 29, 2024
Fidelity Growth Company Fund0.88%746,169761.09KOct 30, 2024
Fidelity Small Cap Index Fund0.56%477,391486.94KAug 30, 2024
Fidelity Growth Company K6 Fund0.52%445,272454.18KOct 30, 2024